Medical Therapy of Aggressive Pituitary Tumors.
Exp Clin Endocrinol Diabetes
; 129(3): 186-193, 2021 Mar.
Article
in En
| MEDLINE
| ID: mdl-33690871
ABSTRACT
The rare aggressive pituitary adenoma presents a special challenge, due to the heterogenous presentation of the disease. The prognosis of aggressive pituitary adenomas has been improved due to recent studies demonstrating clinically-relevant efficacy of temozolomide, which is now considered first-line chemotherapy. However, there is limited data on second-line therapies in patients with treatment failure. This review presents a summary on the potential of medical therapies in aggressive pituitary tumors.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pituitary Neoplasms
/
Enzyme Inhibitors
/
Bevacizumab
/
Temozolomide
/
Immune Checkpoint Inhibitors
/
Antineoplastic Agents
Limits:
Humans
Language:
En
Journal:
Exp Clin Endocrinol Diabetes
Journal subject:
ENDOCRINOLOGIA
Year:
2021
Document type:
Article
Affiliation country:
Alemania